JSPRHealthcareNano-Cap

Jasper Therapeutics, Inc. Insider Trading Activity

Every SEC Form 4 insider transaction reported for Jasper Therapeutics, Inc. (JSPR), sourced directly from SEC EDGAR and updated as new filings are accepted.

Last updated:

Quick Answer

Are JSPR insiders buying or selling?

Jasper Therapeutics, Inc. insiders reported 10 open-market buys ($11.5M) and 26 sells ($2.6M) across 36 Form 4 filings — a net buying position of $8.9M.

Source: SEC EDGAR Form 4

Key Statistics (as of Sep 24, 2025)

Total Form 4 filings
36
SEC EDGAR
Insider filers
12
Insider buys (10)
$11.5M
Insider sells (26)
$2.6M

Insider sentiment

Net buying

Net insider flow of $8.9M in net buying.

Recent JSPR insider transactions

DateInsiderRoleTypeSharesPriceValue
Sep 24, 2025Thomas G WiggansDirectorPurchase41.0K$2.43$99.6K
Sep 24, 2025Svetlana LucasDirectorPurchase20.0K$2.43$48.6K
Sep 24, 2025MARTELL RONPresident and CEOPurchase41.0K$2.43$99.6K
Sep 24, 2025Judith Anne ShizuruDirectorPurchase41.0K$2.43$99.6K
Dec 13, 2024Jeetinder Singh MahalChief Operating OfficerSale900$22.11$19.9K
Sep 12, 2024Jeetinder Singh MahalChief Operating OfficerSale900$21.23$19.1K
Jun 13, 2024Jeetinder Singh MahalChief Operating OfficerSale900$24.16$21.7K
Mar 13, 2024Jeetinder Singh MahalChief Operating OfficerSale900$26.44$23.8K
Feb 12, 2024Carlyle Group Inc.OtherPurchase190.0K$12.95$2.5M
Nov 30, 2023Thomas G WiggansDirectorPurchase10.0K$0.65$6.5K
Nov 22, 2023Thomas G WiggansDirectorPurchase10.0K$0.64$6.4K
Nov 21, 2023Thomas G WiggansDirectorPurchase30.0K$0.61$18.2K
Oct 13, 2023William LisDirectorSale8.0K$0.85$6.8K
Jun 14, 2023Jeetinder Singh MahalChief Operating Officer, Chief Financial Officer and Corporate SecretarySale9.0K$1.66$14.9K
Apr 14, 2023Anna Louise FrenchDirectorSale7.0K$1.48$10.4K
Apr 14, 2023Kurt Von EmsterDirectorSale9.1K$1.49$13.5K
Apr 14, 2023William LisDirectorSale8.5K$1.44$12.2K
Apr 11, 2023Mark Mcdade10% OwnerPurchase2.7M$1.50$4.0M
Jan 31, 2023Carlyle Group Inc.10% OwnerPurchase3.1M$1.50$4.7M
Jan 26, 2023ROCHE HOLDING LTD10% OwnerSale75.0K$1.89$141.8K
Jun 28, 2022William LisDirectorSale49.5K$2.05$101.4K
Apr 23, 2021GLAZER CAPITAL, LLC10% OwnerSale152.9K$9.92$1.5M
Apr 21, 2021GLAZER CAPITAL, LLC10% OwnerSale2.1K$9.97$20.5K
Feb 22, 2021GLAZER CAPITAL, LLC10% OwnerSale12.8K$10.46$134.0K
Feb 9, 2021GLAZER CAPITAL, LLC10% OwnerSale212$10.40$2.2K

Showing the 25 most recent of 36 Form 4 filings for Jasper Therapeutics, Inc..

Most active JSPR insiders

  • GLAZER CAPITAL, LLC15 filings
  • Jeetinder Singh Mahal5 filings
  • Thomas G Wiggans4 filings
  • William Lis3 filings
  • Carlyle Group Inc.2 filings

Ask anything about JSPR insider activity

Use Trabud's AI agent to query Jasper Therapeutics, Inc.'s Form 4 history in plain English — "Show me JSPR CEO purchases this year" or compare it against any other ticker.

Open the AI agent

JSPR insider trading FAQ

Are Jasper Therapeutics, Inc. insiders buying or selling?

Across 36 SEC Form 4 filings, Jasper Therapeutics, Inc. (JSPR) insiders reported 10 open-market purchases totaling $11.5M and 26 sales totaling $2.6M. That is a net buying position of $8.9M.

How many insiders trade JSPR stock?

12 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Jasper Therapeutics, Inc.. The most recent filing was accepted on Sep 24, 2025.

Where does Trabud get JSPR insider trading data?

All JSPR insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.

Looking for another company? Browse all tracked companies.

Related Content